Bladder cancer: A review of non-muscle invasive disease

Cancer Control

Volumn 17, Issue 4, 2010, Pages 256-268

  Sexton, Wade J ^a   Wiegand, Lucas R ^a   Correa, José J ^a   Politis, Christos ^a   Dickinson, Shohreh Iravani ^a   Kang, Loveleen C ^b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b Department of Pathology at the James A Haley Veterans' Hospital ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYLANILINE; 4 BIPHENYLAMINE; ACYLTRANSFERASE; ANALGESIC AGENT; AROMATIC AMINE; BCG VACCINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETHAMBUTOL; GEMCITABINE; GLUTATHIONE TRANSFERASE; INTERFERON; ISONIAZID; MITOMYCIN C; NONSTEROID ANTIINFLAMMATORY AGENT; NUCLEAR MATRIX PROTEIN 22; PHENACETIN; PHENAZOPYRIDINE; PREDNISONE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; THIOTEPA; TUMOR ANTIGEN; VALRUBICIN;

ACCURACY; BLADDER CANCER; BLADDER DISEASE; BONE MARROW SUPPRESSION; CANCER CLASSIFICATION; CANCER GRADING; CANCER INCIDENCE; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CARCINOGENESIS; CARCINOMA IN SITU; CHILL; CHROMOSOME 9Q; CHROMOSOME LOSS; CIGARETTE SMOKING; COMPUTER ASSISTED TOMOGRAPHY; CONSERVATIVE TREATMENT; CYSTECTOMY; CYSTITIS; CYSTOSCOPY; DERMATITIS; DIAGNOSTIC PROCEDURE; DRUG HYPERSENSITIVITY; EARLY INTERVENTION; ECHOGRAPHY; EPIDIDYMITIS; FEVER; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENETIC POLYMORPHISM; HEMATURIA; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; INTRAVENOUS PYELOGRAPHY; MALAISE; MEDICAL ASSESSMENT; MEDICAL DECISION MAKING; MEDICAL LITERATURE; MICTURITION DISORDER; MYCOBACTERIOSIS; OCCUPATIONAL EXPOSURE; PATIENT CARE; PRACTICE GUIDELINE; PROGNOSIS; PROSTATITIS; RASH; RECURRENCE RISK; RETROGRADE PYELOGRAPHY; REVIEW; RISK FACTOR; SEPSIS; SEPTIC SHOCK; SINGLE DRUG DOSE; TISSUE NECROSIS; TRANSURETHRAL RESECTION; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR VOLUME; URINALYSIS; UROGRAPHY;

EID: 77958516512     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327481001700406     Document Type: Review

References (62)

1. American Cancer Society. Cancer Facts and Figures 2009. Atlanta, GA: American Cancer Society; 2009. http://www.cancer.org. Accessed June 4, 2010.
2. Jemal A, Ward E, Hao Y, et al. Trends in the leading causes of death in the United States, 1970-2002. JAMA. 2005;294(10):1255-1259.
3. Fleshner NE, Herr HW, Stewart AK, et al. The National Cancer Data Base report on bladder carcinoma. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1996; 78(7):1505-1513.
4. Lynch CF, Cohen MB. Urinary system. Cancer. 1995;75(1 suppl): 316-329.
5. Linn JF, Sesterhenn I, Mostofi FK, et al. The molecular characteristics of bladder cancer in young patients. J Urol. 1998;159(5):1493-1496.
6. Heney NM, Ahmed S, Flanagan MJ, et al. Superficial bladder cancer: progression and recurrence. J Urol. 1983;130(6):1083-1086.
7. Siefker-Radtke AO, Dinney CP, Abrahams NA, et al. Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D. Anderson cancer experience. J Urol. 2004;172(2):481-484.
8. Kamat AM, Gee JR, Dinney CP, et al. The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma. J Urol. 2006;175(3 pt 1):881-885.
9. Vlaovic P, Jewett MA. Cyclophosphamide-induced bladder cancer. Can J Urol. 1999;6(2):745-748.
10. Hazra A, Gu J, Wu X. Genetic susceptibility to bladder cancer. In: Lerner SP, Schoenberg MP, Sternberg CN, eds. Textbook of Bladder Cancer. Oxford: Taylor and Francis; 2006:2-36.
11. Burch JD, Rohan TE, Howe GR, et al. Risk of bladder cancer by source and type of tobacco exposure: a case-control study. Int J Cancer. 1989;44(4):622-628.
12. Fleshner N, Garland J, Moadel A, et al. Influence of smoking status on the disease-related outcomes of patients with tobacco-associated superficial transitional cell carcinoma of the bladder. Cancer. 1999;86(11):2337-2345.
13. Locke JR, Hill DE, Walzer Y. Incidence of squamous cell carcinoma in patients with long-term catheter drainage. J Urol. 1985;133(6):1034-1035.
14. Murta-Nascimento C, Schmitz-Dräger BJ, Zeegers MP, et al. Epidemiology of urinary bladder cancer: from tumor development to patient's death. World J Urol. 2007;25(3):285-295.
15. Knowles MA. Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? Carcinogenesis. 2006;27(3):361-373.
16. Jocham D, Witjes F, Wagner S, et al. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. J Urol. 2005;174(3):862-866; discussion 866.
17. Filbeck T, Pichlmeier U, Knuechel R, et al. Clinically relevant improvement of recurrence-free survival with 5-aminolevulinic acid induced fluorescence diagnosis in patients with superficial bladder tumors. J Urol. 2002;168(1):67-71.
18. Bastacky S, Ibrahim S, Wilczynski SP, et al. The accuracy of urinary cytology in daily practice. Cancer. 1999;87(3):118-128.
19. Murphy WM, Soloway MS, Jukkola AF, et al. Urinary cytology and bladder cancer. The cellular features of transitional cell neoplasms. Cancer. 1984;53(7):1555-1565.
20. Murphy WM, Crabtree WN, Jukkola AF, et al. The diagnostic value of urine versus bladder washing in patients with bladder cancer. J Urol. 1981;126(3):320-322.
21. Planz B, Jochims E, Deix T, et al. The role of urinary cytology for detection of bladder cancer. Eur J Surg Oncol. 2005;31(3):304-308.
22. Nabi G, Greene D, O'Donnell MO. Suspicious urinary cytology with negative evaluation for malignancy in the diagnostic investigation of haematuria: how to follow up? J Clin Pathol. 2004;57(4):365-368.
23. Lokeshwar VB, Soloway MS. Current bladder tumor tests: does their projected utility fulfill clinical necessity? J Urol. 2001;165(4):1067-1077.
24. Lokeshwar VB, Habuchi T, Grossman HB, et al. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology. 2005;66(6 suppl 1):35-63.
25. van Rhijn BW, van der Poel HG, van der Kwast TH. Urine markers for bladder cancer surveillance: a systematic review. Eur Urol. 2005;47(6):736-748.
26. MP, FinnBladder Group. The role of BTA stat Test in followup of patients with bladder cancer: results from FinnBladder studies. World J Urol. 2008;26(1):45-50.
27. Konety BR. Molecular markers in bladder cancer: a critical appraisal. Urol Oncol. 2006;24(4):326-337.
28. Edge SB, Byrd DR, Compton CC, eds. AJCC Cancer Staging Manual 7th ed. New York, NY: Springer; 2010.
29. Reuter V. Urinary bladder, ureter, and renal pelvis. In: Sternberg SS, ed. Histology for Pathologists. 2nd ed. New York, NY: Lippincott-Raven; 1997.
30. Epstein JI, Amin MB, Reuter VR, et al. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol. 1998;22(12):1435-1448.
31. May F, Treiber U, Hartung R, et al. Significance of random bladder biopsies in superficial bladder cancer. Eur Urol. 2003;44(1):47-50.
32. Kiemeney LA, Witjes JA, Heijbroek RP, et al. Should random urothelial biopsies be taken from patients with primary superficial bladder cancer? A decision analysis. Members of the Dutch South-East Co-Operative Urological Group. Br J Urol. 1994;73(2):164-171.
33. Herr HW. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to Bacillus Calmette-Guérin therapy. J Urol. 2005;174(6):2134-2137.
34. Herr HW. The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol. 1999;162(1):74-76.
35. Herr HW, Donat SM. A re-staging transurethral resection predicts early progression of superficial bladder cancer. BJU Int. 2006;97(6):1194-1198.
36. Hall MC, Chang SS, Dalbagni G, et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol. 2007;178(6):2314-2330.
37. Manikandan R, Lynch N, Grills RJ. Percutaneous peritoneal drainage for intraperitoneal bladder perforations during transurethral resection of bladder tumors. J Endourol. 2003;17(10):945-947.
38. Skolarikos A, Chrisofos M, Ferakis N, et al. Does the management of bladder perforation during transurethral resection of superficial bladder tumors predispose to extravesical tumor recurrence? J Urol. 2005;173(6): 1908-1911.
39. Millán-Rodríguez F, Chéchile-Toniolo G, Salvador-Bayarri J, et al. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol. 2000;164(3 Pt 1):680-684.
40. Babjuk M, Oosterlinck W, Sylvester R, et al. EAU guidelines on nonmuscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2008;54(2): 303-314.
41. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49(3):466-465; discussion 475-477.
42. Günther JH, Jurczok A, Wulf T, et al. Optimizing syngeneic orthotopic murine bladder cancer (MB49). Cancer Res. 1999;59(12):2834-2837.
43. Sidransky D, Frost P, Von Eschenbach A, et al. Clonal origin bladder cancer. N Engl J Med. 1992;326(11):737-740.
44. Sylvester RJ, Oosterlink W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol. 2004;171(6 pt 1):2186-2190.
45. Poppas DP, Pavlovich CP, Folkman J, et al. Intravesical Bacille Calmette- Guérin induces the antiangiogenic chemokine interferon-inducible protein 10. Urology. 1998;52(2):268-275; discussion 275-276.
46. Sylvester RJ, van der meijden AP, Lamm DL. Intravesical Bacillus Calmette-Guérin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 2002;168(5):1964-1970.
47. Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance Bacillus Calmette-Guérin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000;163(4):1124-1129.
48. Nieder AM, Brausi M, Lamm D, et al. Management of stage T1 tumors of the bladder: International Consensus Panel. Urology. 2005;66(6 suppl 1):108-125.
49. O'Donnell MA, Boehle A. Treatment options for BCG failures. World J Urol. 2006;24(5):481-487.
50. Herr HW, Dalbagni G. Defining bacillus Calmette-Guérin refractory superficial bladder tumors. J Urol. 2003;169(5):1706-1708.
51. Belldegrun AS, Franklin JR, O'Donnell MA, et al. Superficial bladder cancer: the role of interferon-alpha. J Urol. 1998;159(6):1793-1801.
52. Grossman HB, O'Donnell MA, Cookson MS, et al. Bacillus Calmette-Guérin failures and beyond: contemporary management of non-muscleinvasive bladder cancer. Rev Urol. 2008;10(4):281-289.
53. O'Donnell MA, Lilli K, Leopold C, et al. Interim results from a national multicenter phase II trial of combination Bacillus Calmette-Guérin plus interferon alfa-2b for superficial bladder cancer. J Urol. 2004;172(3):888-893.
54. Steinberg G, Bahnson R, Brosman S, et al. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guérin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol. 2000;163(3):761-767.
55. Bartoletti R, Cai T, Gacci M, et al. Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a phase II prospective multicenter study. Urology. 2005;66(4):726-731.
56. Dalbagni G, Russo P, Bochner B, et al. Phase II trial of intravesical gemcitabine in Bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder. J Clin Oncol. 2006;24(18):2729-2734.
57. McKiernan JM, Masson P, Murphy AM, et al. Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy. J Clin Oncol. 2006;24(19):3075-3080.
58. Andius P, Fehrling M, Holmäng S. Intravesical Bacillus Calmette-Guérin therapy: experience with a reduced dwell-time in patients with pronounced side-effects. BJU Int. 2005;96(9):1290-1293.
59. Colombel M, Saint F, Chopin D, et al. The effect of ofloxacin on Bacillus Calmette-Guérin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study. J Urol. 2006;176(3):935-939.
60. Durek C, Rüsch-Gerdes S, Jocham D, et al. Interference of modern antibacterials with Bacillus Calmette-Guérin viability. J Urol. 1999;162(6): 1959-1962.
61. Stein JP. Indications for early cystectomy. Urology. 2003;62(4):591-595.
62. International Bladder Cancer Nomogram Consortium, Bochner BH, Kattan MW, et al. Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol. 2006;24(24): 3967-3972.